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Introduction
In the 20th century, the incidence and mortality due to
lung cancer dramatically increased in most European
countries. Despite recent advances in the treatment of
non-small cell lung cancer (NSCLC), clinical out-
comes remain poor. For several decades effective
immune-based anti-tumor therapy has been sought.
There is a strong evidence that the immune system,
when properly stimulated, can eradicate cancer cells.
Dendritic cells are potent antigen-presenting cells
that have been investigated as components of a tumor
vaccine. DCs functions depend not only on the subset
division (the phenotype) but also on the environmental
stimuli (such as cytokines and immunogens) and their
maturation status. The DCs process captures proteins
into peptides that are loaded onto major histocompati-
bility complex class I and II (MHC I and II) molecules,
and these peptide-MHC complexes (pMHC I and II)
are transported to the cell surface for the recognition of
antigen-specific T cells. (pMHC I and pMHC II are
recognized by CD8+ and CD4+ T cells, respectively
[1]. Maturation is a terminal differentiation process
that transforms DCs from cells specialized in antigen
capture into cells specialized in T-cell stimulation.
This process is induced by components of pathogens
or by host molecules associated with inflammation or
tissue injury. Maturation is characterized by the reduc-
tion of phagocytic activity, the development of cyto-
plasmic extensions or "veils", migration to lymphoid
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Abstract: Therapeutic outcomes of definitively treated non-small-cell lung cancer (NSCLC) are unacceptably poor. It has
been proposed that the manipulation of dendritic cells (DCs) as a "natural" vaccine adjuvant may prove to be a particularly
effective way to stimulate antitumor immunity. Presently, there is no standardized methodology for preparing vaccines and
many questions concerning the optimal source and type of antigens as well as maturation state and activity of DCs are still
unsolved. The study population comprised of ten patients with histologically confirmed NSCLC (mean age: 67.63 ± 6.15
years). Resected small tumor pieces were placed in tissue culture dishes containing different growth factors in order to
obtain pure cancer cells. Seven days after the operation, the PBMC were collected and monocytes were purified by the
adherence to culture dishes. Monocytes were cultured in RPMI 1640 medium supplemented with 10% of autologous plas-
ma in the presence of rhIL-4 and rhGM-CSF to generate immature autologous (DCs). TNF-α with or without tumor cells'
lysate were added to maturation of DCs. After 7 days of culture, DCs were harvested and the expression of CD1a, CD83,
CD80, CD86 and HLA-DR antigens were analyzed by flow cytometry. We discovered higher (p=0.07) percentage of semi-
mature DCs in tumor cell lysate culture in comparison with TNF-α culture (21.22 ± 16.82% versus 11.27 ± 11.64%). The
expression of co-stimulatory and maturation markers (CD86, CD83 and HLA-DR) was higher on DCs from the culture with
tumor cell lysate compared with TNF-α culture as a control. Specimen of NSCLC's culture prepared in this way could gen-
erate differences in DCs phenotype, which may have an influence on the therapeutic and protective antitumor immunity of
the vaccine. Our research seems to be the next step in the development of DC-based vaccine. We are going to continue the
investigation to start the preparation of a pattern of immunological vaccine against lung cancer.
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The DCs phenotype varies, depending on the stages
of maturation and differentiation. CD1a is preferen-
tially expressed on human immature myeloid DCs,
whereas CD83 is typically upregulated in response to
the activation stimuli such as TNF-α, TLR, LPS etc.
DCs change their antigen presentation properties dur-
ing maturation. It is well established that immature
DCs are characterized by the intermediate surface
expression of an MHC class II and low level co-stim-
ulatory molecules CD80 and CD86 [4]. CD80 and
CD86 were expressed at high levels on DCs, particu-
larly after maturation. These antigens functioned to
costimulate T cell activation, especially high level pro-
duction of IL-2 that typifies T cell stimulation by DCs.
The function of CD80 and CD86 on DCs in vivo
should be studied directly.
Immunotherapy of cancer is a field of intense
research, especially the induction of active immunity
with either therapeutic or adjuvant purpose. Tumor vac-
cines may have an adjuvant role in surgically resectable
and unresectable NSCLC by consolidating responses to
the conventional therapy. Presently, there is no stan-
dardized method for preparing vaccines and many ques-
tions concerning the optimal source and type of antigens
as well as maturation state and activity of dendritic cells
are still unsolved [5-8]. Therefore, the aim of our study
was to investigate the influence of autologous tumor cell
lysate on the phenotype of dendritic cells generated
from peripheral blood of NSCLC patients.
Materials and methods
Patients. The study population comprised of ten patients with his-
tologically confirmed NSCLC (mean age: 67.63 ± 6.15 years). We
used laboratory tests, chest-X ray, computer tomography, ultra-
sonography and bronchoscopy for the evaluation of lung cancer
stage and the type of disease manifestation. 
Generation of dendritic cells from adherent monocytes. The
blood product, generally 40 ml, was collected aseptically from the
patients and diluted 1:1 with sterile magnesium and calcium free
phosphate buffered saline (PBS). The diluted blood was placed in
15 ml centrifuge tubes and underplayed with Lymphoprep
(Nycomed, Norwegia). The tubes were centrifuged for 20 min. at
400 × g. The buffy coat was removed under the laminar flow hood,
transferred to new tubes and washed twice in full volume PBS. The
harvested PBMC were split into 6-well dishes. The culture medi-
um consisted of RPMI 1640, 10% autologous plasma and 1% v/v
of antibiotics (Penicilin, Streptomycin). The mononuclear cells
were incubated in the culture medium for 1.5 h at 37°C in humid-
ified 5% CO2 atmosphere. After 1,5 h incubation, non-adherent
cells were removed. Adherent cells were then cultured in the pres-
ence of rhGM-CSF (1000 IU/ml, Gentaur, Belgium) and rhIL-4
(500 IU/ml, Gentaur, Belgium). The cytokines were added on 3rd
and 5th days of the culture. Maturation of dendritic cells was
induced on 6th day using tumor cell lysates and TNF-α (1000
IU/ml, Strathmann, Niemcy). In the control culture, the maturation
of DCs was induced only by the stimulation with TNF-α. 
Preparation of tumor cell lysates. After surgical resection, small
tumor pieces were placed in tissue culture dishes in Medium 199
containing different growth factors: (i.a., Medium 199 supple-
mented with 10% fetal bovine serum, EGF, transferrin, insulin,
hydrocortisone, glutamine and antibiotics. The culture plates were
maintained in an appropriate culture microenvironment at 37°C in
a humidified 5% CO2 atmosphere. The medium was changed every
48 hours. After two weeks, confluent cultures of NSCLC cells
were incubated with Trypsin/EDTA-solution for 10 min, carefully
detached with a cell scraper, washed twice in Medium 199, and
centrifuged for 5 min. at 300 × g. The cell suspensions at a densi-
ty 106 cells/ml of Medium 199 were homogenized in four repeat-
ed cycles of freezing at -80°C and subsequent thawing. The lysates
were centrifuged and supernatants were passed through a 0.2 µm
millipore filter. Lysate, prepared on this way, was added to the
dendritic cells culture of DCs.
Flow cytometric analysis. On day 7, at the end of the culture,
supernatants were collected and adherent cells were harvested by
the incubation with Trypsin/EDTA solution. After 15 minutes of
incubation, the floating cells were blended with supernatants,
washed twice in PBS without Ca2+ and Mg2+ and resuspended
prior to immunophenotyping. To characterise the immunopheno-
type of generated dendritic cells, panel of FITC-, PE- or TC-con-
jugated monoclonal antibodies (Becton Dickinson or Caltag, USA)
were used: mouse anti-human IgG1/IgG2a/IgG2a (negative con-
trol), mouse anti-human CD45/CD14, mouse anti-human
CD83/CD1a/HLA-DR, mouse anti-human CD80/CD86/HLA-DR.
The cells were incubated for 20 minutes in dark and after-
wards washed in PBS without Ca2+ and Mg2+. The phenotypic
characterization of DCs was carried out using a FACS Calibur
flow cytometer (Becton Dickinson, USA) and CellQuest soft-
ware. Cytometer was calibrated and mean fluorescent intensity
was calculated.
Statistical analysis. Statistical analysis was performed using the
non-parametric U Mann-Whitney rang test and the Wilcoxon
matched pair test in the Statistica 6.0 software. 
Results
After eight days of DCs cultures using flow cytometry,
cells were harvested and analyzed. According to the
expression of CD1a antigen, we recognized: semi-
mature dendritic cells as CD83+/CD1a+/HLA-DR+
cells; mature dendritic cells as CD83+/CD1a-/HLA-
DR+ cell; immature dendritic cells as CD83-
/CD1a+/HLA-DR+ cells.
Higher (p=0.07) percentage of semi-mature DCs
was discovered in tumor cell lysate culture in compar-
ison with TNF-α culture (21.22 ± 16.82% versus 11.27
± 11.64% respectively). The expression of co-stimula-
tory and maturation markers (CD86, CD83 and HLA-
DR) was higher on DCs from the culture with tumor
cell lysate compared with TNF-α culture. In this study
we observed a significantly higher (p=0.05) expression
of CD83 on CD1a-/HLA-DR+ cells in tumor cell
lysate culture in comparison with TNF-α culture
(275.8 ± 97.08 MFI versus 238.9 ± 64.21 MFI respec-
tively). We also found a significantly higher (p=0,02)
expression of HLA-DR on CD83+/CD1a- cells in
tumor cell lysate culture in comparison with TNF-α
culture (252.16 ± 113.24 MFI versus 203.2 ± 93.03
MFI, respectively) (Fig. 1).
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Fig. 1. Exemplary immunophenotype analyze of dendritic cells generated in cultures with TNF-α (I) and TNF-α plus tumor cells lysate
(II) in NSCLC patient.
More than 95% of cells expressed CD86 antigen.
However, the expression of CD80 was detected only in
less than 15% of cells. The percentage of
CD80+/CD86+ was lower in the culture with tumor cell
lysate compared with TNF-α culture. The population of
CD80-/CD86+ cells was characterized by higher
(p=0.09) expression of CD86 co-stimulatory molecule
in the culture with tumor cell lysate compared with
TNF-α culture (3079.23 ± 964.36 MFI versus 2627.69
± 920.25 MFI, respectively). The CD80-/CD86+ cells
were also characterized by significantly higher (p=0.05)
expression of HLA-DR in the culture with tumor cell
lysate compared with the culture stimulated only with
TNF-α (269.24 ± 159.76 MFI vs. 239.44 ± 138.88 MFI,
respectively) (Table 1 and 2, Fig. 1). 
Our research reveals that DCs-pulsed with tumor
cell lysate has significantly different expressions of
maturation markers and co-stimulatory molecules
compared with DCs generated in the medium contain-
ing only TNF-α.
Discussion
Immature DCs possess high endocytic and phagocyt-
ic capacity permitting Ag capture, but express low
levels of MHC class II molecules and co-stimulatory
molecules on their surface. After microbial infection
and tissue damage, DCs acquire a "mature" pheno-
type and the maturation process is associated with
several coordinated events such as: loss of endocytic
and phagocytic receptors, high level of expression of
MHC class II on the cell surface and the increased
production of co-stimulatory molecules, including
CD80, CD86, CD40 as well as changes in morpholo-
gy [9-11].
Our research showed, that autologous tumor cell
lysate were sufficient to maturate autologous DCs.
High expression of CD83 antigen indicates the change
in maturation state of DCs. Interestingly, in this study
we found that about 95% of cells expressed CD86
antigen, but CD80 antigen was detected only in less
than 15% of cells on Day 9 culture. It seems that tumor
cell lysate or cytokines cause the lack of CD80 antigen
on "exhausted" DCs. It was possible that CD80 anti-
gen could be undetectable by flow cytometry tech-
nique because of its very low expression. In the other
hand, it is possible that CD80 antigens would undergo
fragmentation and desquamation.
We have cultured DCs at the presence of GM-
CSF, IL-4 and TNF-α. GM-CSF stimulates normal
hematopoietic progenitor cells to differentiate in vitro
and form colonies containing granulocytes and
macrophages. Ryncarz and Anasetti have tested the
hypothesis that CD34+/CD86+ cells are the common
precursors of both macrophages and dendritic cells.
CD34+/CD86+ marrow cells cultured in GM-CSF
generated macrophages, but in the presence of GM-
CSF plus TNF-α generated almost exclusively
CD1a+/CD83+ dendritic cells. In contrast,
CD34+/CD86- cells cultured in GM-CSF generated a
predominant population of granulocytes, but in the
presence of GM-CSF plus TNF-α they generated a
variety of cell types. This study suggests that the
expression of CD86 on hematopoietic progenitor
cells is regulated by TNF-α and denotes differentia-
tion towards the macrophages or dendritic cell line-
ages. These results reveal that the stimulation with
TNF-α induces CD86 expression on original
CD34+/CD86- cells. This population of TNF-α-
induced CD86+ cells differentiated into CD1a+ den-
dritic cells in response to GM-CSF, in contrast to
CD34+ cells with constitutive expression of CD86+,
which differentiated into macrophages in response to
GM-CSF. TNF-α, depending on immunophenotypes
of cells and times of culture, could have different
effects [12].
Dilioglous et al. induced human umbilical cord
blood CD14+ monocytes and CD34+ stem cells to dif-
ferentiate into dendritic cells using GM-CSF, IL-4 and
TNF-α. RT PCR revealed that differentiating mono-
cytes initially expressed CD86 mRNA while CD80
468 O. Jankowska et al.
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2008:46(4): 468 (465-470) 
doi: 10.2478/v10042-008-0078-4
Table. 1. The percentage of subpopulations of dendritic cells in
different cultures (*p=0.07).
Table 2. The expressions of maturation markers and co-stimulatory molecules in different cultures (*p=0.09, **p<0.05).
mRNA appeared on Day 2. CD14- and CD34-derived
DCs prior to the functional assay were stimulated
with LPS. A decrease in stimulation, as depicted by
decreased T-cell activation, was significant when
blocking antibodies against both CD80 and CD86
were added into the culture. However, the authors
showed that this effect is detected on stem cell-
derived DCs using only blocking antibodies to CD86
antigen [13]. 
There were many reports suggest that DCs with high
expression of co-stimulatory molecules could be able to
activate cytotoxic T lymphocytes and may be a promis-
ing alternative for cancer immunotherapy but the num-
ber of reports concerning lung cancer is limited.
Ishikawa et al. researched safety and feasibility of
DC-vaccine and showed clinical response in patients
with advanced non-small cell lung cancer or recur-
rent lung cancer received i.v. injections of αGalCer-
pulsed DCs. Immature monocytes-derived DCs
expressed HLA-DR, CD80, CD86, in all prepara-
tions. The expression of CD83 was marginal. Admin-
istration of αGalCer-pulsed DC was well tolerated
and this therapy could be used safely even in patients
with advanced disease [14]. 
Immature DCs were also investigated in the study
by Chang G.C. et al. Autologous DCs were generated
by cells co-cultured with autologous necrotic tumor
cells which were derived from pleural effusion speci-
mens to allow internalization of tumor antigens. It as
shown that the proportion of cells expressing CD83
was higher in DCs co-cultured with TNF-α and with
control PBMC lysate (42.5%) than in those co-cul-
tured with TNF-α and with tumor lysate from a patient
with lung carcinoma (23.8%). Contrary to our study,
this result suggests that co-culture with the tumor
lysate may inhibit the maturation of DCs. Minor to
moderate increases in T-cell responses against tumor
antigens were observed after DC vaccination in six of
eight patients. One patient had minor tumor response
and two patients had a stable disease [15]. 
In the study by Hirschowitz, DCs vaccines were
generated from CD14+ precursors, pulsed with apop-
totic bodies of an allogeneic NSCLC cell line that
overexpressed Her2/neu, CEA, WT1, Mage2. After
that, dendritic cell/T cell-derived maturation factor
(DCTCMF) from culture supernatants was added to
the culture. DCs were partially matured with
DCTCMF that induced surface molecule expression
but minimal cytokine production. Finally vaccine
products were CD14-negative and the cell population
expressed MHC class I (100%) and II (90%), coex-
pressed CD80 and CD86 (60% to 75%) and the mat-
uration marker CD83 (15% to 30%). Six of 16
patients showed an antigen specific response, but
immune responses were independent of stage and
prior therapy. The authors therefore hypothesize that
after the injection partially mature DCs interact with
host inflammatory and resident cells to complete their
maturation in vivo and subsequently induce the
immune responses mentioned in this study [16].
After their first investigation, Hirschowitz et al.
reported the results of a continuation study with simi-
lar inclusion criteria, immunization protocol, and
analysis, using an immature DCs vaccine. The cell sur-
face phenotype of the final vaccine product was as fol-
lows: CD83 about 5%, CD80/86 about 33%. Addition-
al comparison of DCs phenotype revealed similar per-
centage of cells with maturation markers CD80 and
CD83 pre- and post antigen pulsing. Immune respons-
es were observed in 4/7 stage III unresectable, and 6/7
stage I/II surgically resected patients. Results indicate
that immature DCs pulsed with apoptotic tumor cells
have similar biological activity to DCs stimulated with
DCTCMF [17].
Itoh et al. performed a clinical study of a vaccine
using autologous DCs pulsed with CEA652 and
cytokines. Generated DCs showed an immature phe-
notype with high expression of HLA-DR and CD86,
no expression of CD14 and low expression of CD80
and CD83 [18]. Also Babatz et al. conducted a phase
I/II clinical trial to determine the capability of DCs dif-
ferentiated from monocytes and pulsed with a carci-
noembyonic antigen-derived altered peptide (CEAalt)
to induce specific CD8+ T cells in cancer patients.
DCs population showed high percentage of cells
expressing the marker of maturation: CD83 (86%) and
co-stimulatory molecules CD80 and CD86 (93%).
Vaccines prepared in this way efficiently expand pep-
tide-specific CD8+ T lymphocytes in vivo and may be
a promising, safe and feasible alternative for cancer
immunotherapy [19].
Yoshida et al. analyzed the in vitro-responses to
cells from metastatic brain tumor of lung adenocar-
cinoma using DCs from the peripheral blood. They
found that the matured DCs, stimulated with autolo-
gous tumor lysates, displayed the typical surface
phenotype of CD3+, CD45+, CD80+, CD86+ and
developed a strong cytotoxic T lymphocyte activity
[20]. 
The present study suggests that autologous DCs
loaded with tumor antigens are fully competent and
could present cancer antigens to T lymphocytes. A vac-
cine prepared in this way could serve as a novel
immunotherapy method in lung cancer treatment.
Presently, there is no standardized methodology for
preparing vaccines and many questions concerning the
optimal source and type of antigens as well as matura-
tion state and activity of dendritic cells (DCs) are still
unsolved. Our research seems to be the next step in the
development of DC-based vaccine. We are going to
continue the investigation to elaborate a pattern of
immunological vaccine against lung cancer.
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